Amgen (AMGN) Laps the Stock Market: Here's Why

12.04.24 00:00 Uhr

Werte in diesem Artikel
Aktien

291,65 EUR 3,55 EUR 1,23%

Indizes

PKT PKT

39.709,4 PKT -163,6 PKT -0,41%

18.675,7 PKT -38,2 PKT -0,20%

16.779,4 PKT -53,2 PKT -0,32%

2.525,2 PKT -10,5 PKT -0,41%

5.305,6 PKT -15,9 PKT -0,30%

Amgen (AMGN) ended the recent trading session at $270, demonstrating a +1.33% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.74%. Meanwhile, the Dow experienced a drop of 0.01%, and the technology-dominated Nasdaq saw an increase of 1.68%.Shares of the world's largest biotech drugmaker have depreciated by 3.46% over the course of the past month, outperforming the Medical sector's loss of 4.72% and lagging the S&P 500's gain of 0.8%.The upcoming earnings release of Amgen will be of great interest to investors. The company's earnings report is expected on May 2, 2024. The company is forecasted to report an EPS of $3.83, showcasing a 3.77% downward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $7.44 billion, reflecting a 21.93% rise from the equivalent quarter last year.Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $19.49 per share and revenue of $32.94 billion, indicating changes of +4.5% and +16.83%, respectively, compared to the previous year.Investors should also note any recent changes to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.07% higher. Currently, Amgen is carrying a Zacks Rank of #3 (Hold).In the context of valuation, Amgen is at present trading with a Forward P/E ratio of 13.67. For comparison, its industry has an average Forward P/E of 23.42, which means Amgen is trading at a discount to the group.It is also worth noting that AMGN currently has a PEG ratio of 2.52. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.9 based on yesterday's closing prices.The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 82, putting it in the top 33% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Amgen

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Amgen

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Amgen Inc.

Analysen zu Amgen Inc.

DatumRatingAnalyst
28.04.2021Amgen buyGoldman Sachs Group Inc.
28.04.2021Amgen NeutralJP Morgan Chase & Co.
05.03.2021Amgen buyGoldman Sachs Group Inc.
05.03.2021Amgen NeutralJP Morgan Chase & Co.
23.12.2020Amgen Sector PerformRBC Capital Markets
DatumRatingAnalyst
28.04.2021Amgen buyGoldman Sachs Group Inc.
05.03.2021Amgen buyGoldman Sachs Group Inc.
15.03.2019Amgen OutperformBMO Capital Markets
17.01.2019Amgen buyGoldman Sachs Group Inc.
08.12.2018Amgen buyGoldman Sachs Group Inc.
DatumRatingAnalyst
28.04.2021Amgen NeutralJP Morgan Chase & Co.
05.03.2021Amgen NeutralJP Morgan Chase & Co.
23.12.2020Amgen Sector PerformRBC Capital Markets
29.07.2020Amgen NeutralJP Morgan Chase & Co.
25.01.2020Amgen NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
15.11.2012Amgen verkaufenHamburger Sparkasse AG (Haspa)
31.07.2012Amgen verkaufenHamburger Sparkasse AG (Haspa)
01.02.2012Amgen verkaufenHamburger Sparkasse AG (Haspa)
20.12.2011Amgen verkaufenHamburger Sparkasse AG (Haspa)
30.07.2008Amgen UpgradeIndependent Research GmbH

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amgen Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"